Prof. Dr. Henderik W. Frijlink
|
|
- Osborn Stevenson
- 5 years ago
- Views:
Transcription
1 Pulmonary drug administration technologies to improve the therapy in Asthma, COPD and beyond. Prof. Dr. Henderik W. Frijlink Department of Pharmaceutical Technology and Biopharmacy University of Groningen founded in 1614
2 2 Content The basics of pulmonary drug administration Dry powder inhalers: new insights in powder formulations and powder dispersion into an aerosol Beyond asthma and COPD: new therapies applying the pulmonary route of drug administration via the Twincer inhaler
3 (%) The basics of drug inhalation The efficacy of inhaled drugs is determined by a combination of: penetration of aerosolized particles into the airways deposition of these particles on the mucus Upper throat deposition Only particles within the 1 5 µm size range are able to penetrate into the deeper airways and deposit there Sedimentation Diffusion and exhalation penetration / deposition Penetration in target area Deposition Preferred particle size aerodynamic part. diameter ( m m)
4 percent of real dose (%) What is the optimal size of the aerosol? Mono-disperse aerosols of different particle size ( μm) Inhaled at different inhalation flow rates 31 and 67 l/min) exhaled oropharynx central + intermediate peripheral micron 3.0 micron 6.0 micron flow rate (l/min) Aerodynamic diameter: μm From Usmani et al., AJRCCM 2005, Re-calculated by A.H.de Boer (Groningen)
5 % exhaled/settling time (s) Are smaller particle sizes of the aerosol better? % exhaled at 31 L/min % exhaled at 67 L/min settling time (s) particle diameter (µm) From Usmani et al., AJRCCM 2005, Re-calculated by A.H.de Boer (Groningen) No: At particle sizes below 1 mm exhalation > 50% Because settling times of these small particles will be over 10 seconds
6 12 Inhaler development philosophy Good performance of an inhaler can only be achieved upon adequate balancing of the three major forces involved Formulation Device Patient surface tension or interparticular forces Break-up or deagglomeration forces during inhalation deposition forces in the human lungs
7 Systems for pulmonary drug administration Objectives: To generate at the right moment an aerosol of the preferred particle size distribution and containing the adequate dose. Moment: at the start of the inhalation (<2 l) Particle size: 1-5 mm Dose: 4 mg 400 mg Prevent high inhalation flow rates Increase the duration of the inhalation cycle Simple and fast (<1 min) administration 13
8 14 percent deposition (%) depositiefractie Prevent high inhalation flow rates µm particles higher airways lower airways 0,12 0,10 0,08 0,06 12 L/min 42 L/min 60 L/min 40 0,04 0, , luchtweg generatie Inhalation flow rate (l/min) Data from Byron, Respiratory Drug Delivery, 1990, The deposition in the lower airways is strongly reduced at increased inhalation flow rates (more forceful inhalation)
9 15 The duration of the inhalation cycle and breath-hold Deposition fraction in the target area (deeper airways) by sedimentation Particles of 1 µm * Mean airway diameter in generations ( mm) T = 0 *Normalised lung volume 1 liter 4.2 l in 6 l lung volume Distance fallen 3 s Distance fallen 6 s from Byron, Respiratory Drug Delivery, 1990
10 16 Inhalation systems Jet and ultrasonic nebulizers Metered dose inhalers (with spacers) Dry powder inhalers: dpi s Soft mist inhalers Pari LC Sprint Flixotide MDI Respimat Genuair
11 Dry powder inhaler (DPI) Breath-controlled, breath-actuated 30 to 40 % (deep) lung deposition possible No propellant, minimal use of excipients? Stable formulations possible For processing agglomerated particles required In the aerosol de-agglomerated particles required Formulation difficult 17
12 What makes a good dry powder inhaler An increasing fine particle dose with increasing flow rate A medium to high air flow resistance A high delivered fine particle dose (FPD) preferably between 1.5 and 3 µm Minimal inter-dose, -device and batch-tobatch variation A robust design, easy to use 18
13 19 Functional parts of a DPI Mouthpiece Powder disperson system (disintegration principle) Powder formulation Dose measuring system Or preloaded cartidges
14 Powder formulations for particles of 2-5 mm 20 Soft spherical pellets Micronized drug cohesive forces instable good de-agglomeration adhesive mixtures Micronized drug with (larger) carrier crystals adhesive and cohesive forces stable systems Difficult deagglomeration
15 21 Understanding DPI performance Return to basic philosophy The functionality of a DPI is reached via an adequate balancing between: Co- and adhesion forces in the powder Disintegration forces Long deposition forces Powder mixture Inhaler design Patient
16 Simple model: energy ratio 2/27/ Energy Binding energy (E b ): energy required for detachment Separation energy (E s ): energy put into separation of the drug particle during inhalation Energy ratio: E s /E b if 1, then detachment occurs 22
17 Energy ratio for individual drug particles Binding energy (incl. binding to apparent carrier surface sites ) From: Hickey et al, J. Pharm. Sci. 96 (2007) Susceptibility to separation energy Carrier surface site activity (inversely proportional to energy ratio) 23 From: De Boer et al, Int. J. Pharm. 260 (2003)
18 24 Cum. drug mass (%) Energy ratio distributions may help to understand and explain (principle) 100 Drug detached (low flow rate) Drug detached (high flow rate) 0 1 Energy ratio (E s /E b )
19 Adhesive mixtures for inhalation: How to study the model? Carrier residue Process variables Mixing time Mixing intensity Mixing principle Mixture variables Drug load Drug agglomeration Drug detached Component variables Type of drug Drug content Carrier size fraction (Added) lactose fines or other excipients 25 Inhalation variables Flow rate Dispersion principle
20 A model including the basic variables and interactions 26 De Boer et al., Advanced Drug Delivery Reviews, 2012 (64),
21 27 Methods: A practical approach Design a simple model/method to measure (1) drug detachment and (2) carrier residue: test inhaler Study the effects of formulation variables such as drug content-lactose types-excipients-etc. Study the effect of process variables: mixing time-mixing forces-etc. Measure the effects at different separation energies: vary with flow rates
22 28 Methods: the test inhaler F c De-agglomeration based on impaction forces, optimal use of inhalation energy Release based on separation by size F d carrier with attached drug detached drug Drug on the carrier remains in the cyclone chamber: carrier residue Detached drug will leave the cyclone chamber
23 Drug detached (%) What s the effect of mixing time? n = 5 60 So there is no straightforward answer! it depends min 420 min 0.5 min 420 min 0.5 min 420 min 0.5 min 420 min 0.5 min 420 min SX; coarse; 20 L/min FP; coarse; 20 L/min SX; fine; 20 L/min SX; coarse; 60 L/min SX; fine; 60 L/min 29 SX: salmeterol xinafoate, FP: fluticason propionate
24 Drug detached (%) What s the effect of drug content? 100 n = it depends 0.4% 4% 0.4% 4% 0.4% 4% 0.1% 0.4% 10 min; 20 L/min 10 min; 40 L/min 2 min; 20 L/min 10 min; 20 L/min 30 BUDESONIDE
25 31 Drug detached (%) What s the effect of added fine lactose? n = cause Can t it depends tell, 0% 4% 0% 4% 0% 4% 0% 4% 0% 4% Fine; 0.4%Bud 20 L/min Fine; 0.4%Bud 50 L/min Coarse; 0.4%Bud 20 L/min Fine; 4%Bud 20 L/min Fine; 4%Bud 50 L/min
26 32 Cum. drug mass (%) Energy ratio distributions may help to understand and explain (a change in formulation) 100 Positive effect on drug detachment at low flow rate No effect on drug detachment at intermediate flow rate Negative effect on drug detachment at high flow rate 0 1 Energy ratio (E s /E b )
27 Drug detached (%) Drug detached (%) The effect of mixing time %, 2 minutes 0.4%, 2 0.4%, minutes 2 minutes 4%, 60 minutes 0.4%, 600.4%, minutes 60 minutes Flow Flow rate rate (L/min) (L/min) Airbag effect 33 Salbutamol sulphate on lactose µm, testinhaler C-VI
28 Turbula Blender 90 RPM, 10 min. Carrier lactose: µm 34 The effect of drug content
29 The role of (lactose) fines Presumed roles Occupation of active carrier sites Filling up of surface discontinuities Co-agglomeration with drug particles Buffer between colliding carrier particles 35 What is a fine? At what size is a fine a fine? Do all fines five the same effects at all drug loads?
30 Effect of size of the fines Budesonide: X 50 = 1.48 μm Lactose fines coarse : X 50 = 3.78 μm Lactose fines fine : X 50 = 1.52 or 2.00 μm Lactose carrier: μm Drug load: 4% coarse fines fine fines 36
31 SEM: for explanation After inhalation without fines + 4% w/w coarse lactose fines coarse fines: No break-up of agglomerated drugs and no press-on forces % w/w fine lactose fines fine fines: Distribution of agglomerated drugs and press-on forces
32 Effect of size of the fines: effect of payload Budesonide: X 50 = 1.48 μm Lactose fines coarse : X 50 = 3.78 μm Lactose fines fine : X 50 = 2.00 μm Lactose carrier: μm Drug load: 0,4% coarse fines fine fines 38
33 Adhesive mixtures for inhalation: Try to understand the interactions! Lactose Carrier residue Component variables Type of drug Drug content Carrier size fraction (Added) lactose fines 39 + Process variables Mixing time Mixing intensity Mixing principle Inhalation variables Flow rate Dispersion principle INTERACTIONS! Fine Particle Fraction (FPF) Detached drug
34 40 Conclusions from powder studies Multi-order interactions omnipresent. Their understanding crucial for mixture optimisation Developing or optimizing techniques to measure relevant mixture properties is probably the most important challenge in the near future
35 SEM and CARS: for explanation Coherent anti-stokes Raman scattering (CARS): SEM: 41 Andrew L. Fussell Herman Offerhaus Scale bar: 20 µm
36 The role of additives Various additives found in literature: Lactose fines force control agents Purpose: magnesium stearate, l-leucine, etc. Occupation/inactivation of active sites Change the apparent payload Change (reduce) the co- and adhesive forces Protect drug particles from press-on forces during mixing 42
37 A model including the basic variables Additives 43 De Boer et al., Advanced Drug Delivery Reviews, 2012 (64),
38 Effect of force control agents Lactose Process A: smoothed lactose Process B: smoothed lactose with Mg-Stearate (0,25%) Mixtures with beclomethason dipropionate (0.8%) AFM: force of adhesion (separation energy) FPF (60 l/min) From: Young et al, J. Pharm. Pharmacol., 2002, 54,
39 Additives may interfere at the level of Adhesion forces between drug and carrier: Increases FPF Cohesion forces between the drug particles: May decrease FPF but on the other hand reduce aerosol particle size The mixing process: Increase or decrease the FPF (increase or decrease press-on forces) affect re-distribution etc. The inhalation process: Increasing or decreasing detachment forces (seperation energy) increasing or decreasing FPF 45
40 Generation of the aerosol in a DPI: a balance between binding forces and de-agglomereation forces moderate good poor Powder formulation Desintegration principe 46 Binding forces: v.d. Waals forces surface irregularities impurities capillaire forces electrostatic forces De-agglomeration forces: shear and friction forces Drag and lift forces Impaction forces
41 Forces for de-agglomeration Friction forces Drag and lift forces Inertial forces Single particles Agglomerates 47 Inertial forces largest (sponge with water) Can we apply these forces?
42 The DPI problem: dispersion of agglomerates using energy from air De-agglomeration of cohesive powders in 1-3 mm aerosols? 48 Shear forces Turbulent air Moving capsule Impaction forces
43 The fine particle fraction as function of the inhalation flow rate 49 Inhalers that generate a FPF that is dependent on the inhalation flow rate. Inhalers that generate a FPF that is independent from the inhalation flow rate.
44 50 percent deposition (%) The effect of high inhalation flow rates higher airways lower airways Inhalation flow rate (l/min) Data from Byron, Respiratory Drug Delivery, 1990, The deposition in the upper airways (throat) is strongly increased at increased inhalation flow rates (more forceful inhalation)
45 51 Fine particle fraction [%] Constant lung-dose because of inhalation flow dependent FPF generation 50 Fine particle fraction at different inhalation flows Novolizer Diskus flow [ln/min] To compensate for the increased loss by oropharyngeal impaction at increased flow rates the fine particle dose must increase to keep the lung dose constant
46 fijne deeltjesfractie [%] dose The idea behind the fow dependent DPI lungdose FPF rel. throath deposition rel. lungdeposition The increase in FPF at increasing inhalation flow results in a constant lung dose 52 inhalation fl;ow Fijne deeltjesfractie als functie van het inhalatiedebiet flow rate [l/min]
47 Deposition [%] Constant lung-dose because of inhalation flow dependent FPF generation percent of nominal dose (%) percent of nominal dose (%) Periferal lung deposition upper airways cental and peripheral Novolizer pressure drop (kpa) Inhalation flow PIFR [L/min] From: Newman et al., Eur. Respir. J., 2000,16, Diskus upper airways central and peripheral pressure drop (kpa)
48 Long depositie [% van de totale lichaamsdosis] Lung deposition from Turbuhaler in children Oropharyngeal deposition [% of total body deposition] lung deposition of budesonide with Turbuhaler throath deposition of budesonide with Turbuhaler years 9-12 years years years 9-12 years years 54 From: Devadason SG, et al., Eur Respir J Sep;10(9):
49 The importance of good inhalation devices Serum levels (% van C max ) of formoterol after inhalation via: (n=29) Cyclohaler Novolizer Pulmonary Oral absorption Pulmonary Oral absorption From: 55 Petzold et al., J Aerosol Med Pulm Drug Deliv Sep;21(3):
50 The Twincer : A disposable DPI for high powder doses Highly efficient de-agglomeration: Varying doses up to 60 mg in one inhalation (two diametrically placed cyclones) Flexible application: large industry to SME Do it yourself inhaler (weigh-seal-click) Disposable: Infections (originally Cystic Fibrosis) Single use (e.g. vaccination, emergencies, offperiods etc) Cheap: Only three parts of plastic and a blister (or a cover foil) Complete moisture protection Simple to use 56
51 Simple to use Remove cover foil Inhale Dispose inhaler (disposable, recyclable plastic) 57
52 58 Computational fluid dynamics and computational particle tracking Calculate air flow rate Inlet powder channel Inlet classifier bypass Inlet bypass level 2 Calculate particle residence time Passage of 1 μm particles Passage of 10 μm particles Retention of carrier particles
53 Efficient aerosol generation of doses up to 60 mg per inhalation percent in class (%) Different doses of colistin sulfomethate were aerosolized, and the particle size distribution of the aerosol was determined Even at 60 mg the size distribution of the aerosol is only marginally changed compared to 25 or 8 mg powder doses dose is 8 mg dose is 25 mg dose is 60 mg 4 0 0, upper class limit (µm)
54 60 Twincer dispersion efficiency Aerosol: particle size, flow rate, indication Sustainability/robustness of device: pollution, wear, price Contamination, complexity, ease of use, patient abilities Use of battery, etc. System l/min X 50 (mm) Rel. width X90-X10 Pulmicort mdi (CFC) QVAR mdi (HFA) Pari LC Plus Soft mist: Pari eflow Soft mist: Respimat Soft mist: Handspray DPI: Twincer (25 mg dose) X50
55 Examples of new dry powder inhalation therapies: current studies in man Colistimethate in cystic fibrosis Tuberculosis: Colistimethate Kanamycin Tobramycin in bronchiectasis: Levodopa in Parkinson s disease Adenosine as bronchial provocation agent 61 Influenza vaccination
56 Colistimethate-Twincer studies in CFpatients 10 patients Inhaler: Twincer : Colistin sulphomethate 25 mg (2x12.5 mg) 16.7% sweeper lactose X 10 : 0.7 mm, X 10 : 1.6 mm, X 90 : 3.1 mm Nebulizer (Ventstream -PortaNeb ): 158 mg colistin sulphomethate solution Pulmonary function tests: FEV 1 and FVC Breathhold: 2-3 sec Questionnaire 62
57 Colistimethate-Twincer studies in CFpatients II 23 mg Relative bioavailability compared to nebulizer: % 160 mg per neb. = 55 mg per DPI Patient satisfaction score: 9 excellent positive 1 good mg 4 patients mild cough with both administrations Extremely robust performance of the Twincer : Inhalation profile Particle size of powder Breath hold
58 Robustness of the Twincer 10 patients Inhaler: Twincer : 64 Colistin sulphomethate 25 mg (2x12.5 mg) 16.7% sweeper lactose X 10 : 0.7, X 50 : 1.6, X 90 : 3.1 mm PIF through inhaler: 67.9 l/min ( ) Breathhold: 2-3 sec Relative Nebulizer bioavailability: (Ventstream- PortaNeb): Rel. complete dose: 270% Rel. 158 mg emitted colistin dose: solution 140% CPulmonary function tests: max : 66.3 μg/ml (41-91) FEV 1 and FVC t max : 0.86 h ( ) 7 patients Inhaler: Twincer : Colistin sulphomethate 25 mg (2x12.5 mg) 16.7% sweeper lactose X 10 : 0.9, X 50 : 2.1, X 90 : 3.8 mm PIF through inhaler: 43.9 l/min ( ) Breathhold: >7 sec Nebulizer Relative bioavailability: (Ventstream- PortaNeb): Rel. complete dose: 300% 158 Rel. mg emitted colistin dose: solution 140% Pulmonary C function tests: max : 62.7 μg/ml (38-87) FEV 1 and FVC t max : 0.74 h ( )
59 Tuberculosis: The rapid development of MDR and XDR TB Tuberculosis, pulmonary bacterial infection: 1.7 billion carriers of latent TB Rapid growth of multi-drug en extremely drug resistant TB new MDR-TB cases per year 1 out of 2 MDR-TB patients dies form the disease , 9728, 2010, Proportion of multidrug-resistant disease among (A) new cases and (B) previously treated cases of tuberculosis Based on Global Drug Resistance Surveillance Project data.19 and 32 Australia, Democratic Republic of the Congo, Fiji, Guam, New Caledonia, Solomon Islands, and Qatar reported data for combined new and previously treated cases.
60 The size of the MDR en XDR-TB problem World: 9 million new TB patients per year ( MDR-TB) Bejing (18 MM inhabitants) 500 new patients with MDR-TB per month Survival after sputum collection in patients with XDR tuberculosis Kaplan-Meier survival curve depicting the rapid mortality among 52 of 53 patients with XDR tuberculosis and confirmed dates of death in an outbreak in a rural area in KwaZulu-Natal, South Africa. 66
61 Reasons to treat MDR and XDR TB with inhaled antibiotics 1. To obtain a high concentration at the infection site in the lungs: Resistant strains are 10 times less sensitive to the antibiotic, so an over 10 times higher drug concentration might be interesting Reduced systemic exposure may reduce side-effects and allow higher dosing 2. Reduction of transmission 3. Prevent the development of new resistant strains 4. Compared to injection inhalation: Is cheaper and easier Non-invasive Requires no medically trained personnel, only for instruction Has no transmission risks from disposed needles 67
62 air velocity (m/s) A reduced chance of transmission? Transmission of the disease occurs via airborne TB containing droplets generated during cough The source of the TB containing aerosol is the mucus in the conducting airways from which the infected droplets are entrained l/min 60 l/min 90 l/min airway generation
63 Inhaled colistimethate in the treatment of MDR-tuberculose TB exposure stopped to Animal Rooms Guinea Pig Cohort Receiving Aerosols from TB Ward A B A B B A B A A B A B B A B A Inhaled Administration to TB Patients ST only ST + IA ST only ST + IA ST + IA ST only ST + IA ST only ST only ST + IA ST only ST + IA ST + IA ST only ST + IA ST only Infectious Patient Group 1 Patient Group 2 Patient Group 3 Patient Group 4 Source TST-1 TST-2 TST-3 TST-4 TST-5 TST-6 Table 1: A schematic of key events during the course of the proposed study. Six MDR-TB patients, forming a patient group, will provide the infectious aerosols to expose susceptible guinea pigs in the study. Each Patient Group is required to remain in the TB Ward of the AIR facility for four weeks, after which a new set of 6 patients will be admitted. There are most 4 patient 24 patiënts 2 weeks treatment 3x daily 25 mg inhaled colistimethate groups recruited over the course of four months. After the Patient Group 4 is discharged from the study, only activities regarding the guinea pigs are maintained. Tuberculin Skin Tests are adminsitered to guinea pigs at six time points: before start of the study, at 4, 8, 12, 16, and finally 20 weeks. Air from the ward is directed to Guinea Pig Cohort A when patients are on as add-on therapy to standard therapy systemic therapy (ST) alone, while air is directed to Guinea Pig Cohort B when patients are receiving an inhaled antimicrobial (IA) on top of systemic therapy. 69
64 70 How to measure transmission AIR, Experimental Plan Guinea Pig Air Sampling A B Guinea Pig TB RFLP Odd days Even days UVGI or other intervention 3 patient rooms Plus common areas Intervention on/off on alternative days Pt. TB RFLP
65 Results so far: Guinea pig infections per cohort: control group intervention group Total: % reduction in transmission Significant reduction in mucosal TB Furture: 71 New study: 3x daily inhalation of 50 mg colistimethate Kanamycin inhaled via the Cyclops inhaler (Twincer variant)
66 Influenza and the vaccine Problems related to the flu vaccination: Vaccine (HA) is instable Aqueous suspension: 6-12 months at 4-10 C Fear for the needle (15-35%) Injected vaccine is effective in only 50-70% of the population over 65 year old Current vaccination does not protect against drifted and shifted influenza strains (yearly vaccination required) Medically trained personal necessary for administration Inhalation administers the vaccine via the natural route of infection Needle free Self-administration possible An immune response at the site of infection (mucosal immunity in the airways) No adjuvants needed 72
67 Particle engineering for the production of a stable inulin based powder with subunit vaccine September 15, 2010 at 10:13 AM Spray-freeze dried particles Vaccine 3 months 3 years Liquid vaccine (4 ºC) 100% <5% Powder spray dried (20 ºC) 100% 100% Powder spray freeze dried (20 ºC) 100% 97% Spray dried particles PATH grant aims to improve shelf life of pandemic flu vaccines By Kristi Heim Seattle global health nonprofit PATH received a $5.2 million contract from the federal government to develop stable pandemic influenza vaccines, which could help extend the shelf life and stockpile more of the vaccine. The contract from the Biomedical Advanced Research and Development Authority (BARDA), a division of the US Department of Health and Human Services, could lead to an additional $4.2 million in funding from BARDA in the project's second phase. 73 J. Contr. Rel., 144, , 2010
68 Vaccine, 25, , Pulmonary administration of inulin stabilized influenza vaccine powder to mice Balb/c mice, subunit A/Panama/2007/99 vaccine (H3N2) Vaccine administrations: Intramuscular: 5 ug vaccine Intrapulmonary: 5 ug vaccine as liquid Intrapulmonary: 5 ug vaccine as inulin stabilized powder Prime + two boosters: day 0, 14 and 28 Systemic immune response at day 42: 10 log serum-igg titer intra aerosol powder muscular inhalation inhalation * 2 log HI titer * p<0.01 intra aerosol powder muscular inhalation inhalation i.m a.i. p.i.
69 75 Pulmonary administration of inulin stabilized influenza vaccine powder to mice Mucosal immune response: Nose Lung 10 log Ig titer IgG IgA 1/8 5/8 2/8 *p<0.05 6/8 * p<0.01 7/8 * p<0.001 * p<0.001 Intra i.m. aerosol a.i powder p.i. muscular inhalation inhalation Conclusions: Improved immune response in mice compared to intramuscular administration: Systemic and mucosal response (incl. IgA) Cross protection against drifted virus variants Protection at the port of entry of the virus Pulmonary influenza vaccination requires no adjuvant Non-invasive administration
70 J. Contr. Rel., 144, , 2010 Step into humans Successful studies date already 40 years back! Influenza antibody response following aerosal administration of inactivated virus. Waldman RH, Wood SH, Torres EJ, Small PA Jr. Am J Epidemiol Jun;91(6): Immunization against influenza. Prevention of illness in man by aerosolized inactivated vaccine. Waldman RH, Mann JJ, Small PA Jr. JAMA Jan 20;207(3): A comparative trial of influenza immunization by inhalation and hypojet methods. Haigh W, Howell RW, Meichen FW. Practitioner Sep;211(263): spray-freeze dried and spray dried powders from the Twincer Cascade impactor results 76
71 77 The Twincer : inhalation of 50 mg colistin sulfomethate
72 Thanks Floris Grasmeijer Anne H. de Boer 78 Literature: Grasmeijer F, Hagedoorn P, Frijlink HW, de Boer AH. Drug content effects on the dispersion performance of adhesive mixtures for inhalation. PLoS One Aug 14;8(8):e doi: /journal.pone ecollection Grasmeijer F, Hagedoorn P, Frijlink HW, de Boer HA. Mixing time effects on the dispersion performance of adhesive mixtures for inhalation. PLoS One Jul 2;8(7):e doi: /journal.pone Print 2013 Grasmeijer F, Lexmond AJ, van den Noort M, Hagedoorn P, Hickey AJ, Frijlink HW, de Boer AH. New Mechanisms to Explain the Effects of Added Lactose Fines on the Dispersion Performance of Adhesive Mixtures for Inhalation PLoS ONE 9(1): e doi: /journal.pone Grasmeijer F, Frijlink HW, de Boer AH. A proposed definition of the activity of surface sites on lactose carriers for dry powder inhalation. Eur J Pharm Sci Submitted de Boer AH, Chan HK, Price R. A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect? Adv Drug Deliv Rev Mar 15;64(3):257-74
73 79 That s a great question!! Come to think of it, I m not sure what it is I m trying to tell you Questions
University of Groningen. Optimisation of dry powder inhalation Boer, Anne Haaije de
University of Groningen Optimisation of dry powder inhalation Boer, Anne Haaije de IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationPulmonary deposition of inhaled drugs
Pulmonary deposition of inhaled drugs Federico Lavorini Dept. Experimental and Clinical Medicine Careggi University Hospital Florence - Italy Presenter Disclosures F.L. has received in the last 5 years
More informationCitation for published version (APA): Westerman, E. M. (2009). Studies on antibiotic aerosols for inhalation in cystic fibrosis s.n.
University of Groningen Studies on antibiotic aerosols for inhalation in cystic fibrosis Westerman, Elisabeth Mechteld IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF)
More informationDry Powder Inhaler. Developing an Efficient. 3M Conix DPI. White Paper / Spring Proven Solutions that Enable Your Success
3M Drug Delivery Systems Developing an Efficient Dry Powder Inhaler 3M Conix DPI White Paper / Spring 2011 Proven Solutions that Enable Your Success Introduction introduction Inhalation drug delivery has
More informationThe influence of lactose particle size on dry powder inhalation performance
The influence of lactose particle size on dry powder inhalation performance MCC Starch Lactose Inhalation Superdisintegrants 1 Introduction In most dry powder inhalation (DPI) formulations carriers are
More informationCLINICAL RELEVANCE OF IN VITRO PARTICLE SIZING DATA. Steve Newman, PhD Nottingham, UK November 2006
IPAC-RS Conference 6-8 November 2006 CLINICAL RELEVANCE OF IN VITRO PARTICLE SIZING DATA Steve Newman, PhD Nottingham, UK November 2006 IPAC-RS Conference 6-8 November 2006 1 EFFECT OF PARTICLE SIZE ON
More informationCOMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES
COMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES Miriam Sanz Cermeño and Helena Maria Cabral Marques UCTF, Faculdade de Farmácia, Universidade de Lisboa, PORTUGAL 1. Introduction Inhalation
More informationUniversity of Groningen. Technology in practice Lexmond, Anne
University of Groningen Technology in practice Lexmond, Anne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationPatient. Device Clinician. Safety & efficacy
Patient Device Clinician Formulation Safety & efficacy 1. Modified from Daley-Yates et al., Expert Opin. Drug Deliv. 2011: 8(10):1297-1308 2. Modified from Laube et al., Eur Respir J 2011; 37: 1308 1331
More informationUniversity of Groningen. Optimisation of dry powder inhalation de Boer, Anne
University of Groningen Optimisation of dry powder inhalation de Boer, Anne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationInfluence of blender type on the performance of ternary dry powder inhaler formulations
Institute of Pharmacy Kiel University Influence of blender type on the performance of ternary dry powder inhaler formulations Mats Hertel Theoretical background Binary formulation: 1 st blending Ternary
More information21/03/2011 AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY. Fundamentals of aerosols
AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY Steve Newman Scientific Consultant Norfolk, UK steve.newman@physics.org
More informationAEROSOL THERAPY: THE PRACTICALITIES
AEROSOL THERAPY: THE PRACTICALITIES Lester I. Harrison, PhD Section Head, Clinical Pharmacokinetics, 3M Pharmaceuticals, 3M Center 270-3S-05, St. Paul, MN, USA 55144 liharrison@mmm.com Introduction: Horses,
More informationCOPD Device Workshop. Summary. Role of inhaler device in COPD. Why use inhaler device in COPD?
Part 1 Role of inhaler device in COPD COPD Device Workshop Dr Philip Lee Respiratory and Sleep Physician St George Hospital, Sydney Part 2 Part 3 Part 4 Incorrect inhaler technique-adverse clinical outcomes
More informationUniversity of Groningen. Optimisation of dry powder inhalation de Boer, Anne
University of Groningen Optimisation of dry powder inhalation de Boer, Anne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationThe Use of Physics-Based Modeling to Better Design Drug- Device Interface. Yoen-Ju Son, PhD Merck Research Laboratory, Summit, NJ
The Use of Physics-Based Modeling to Better Design Drug- Device Interface Yoen-Ju Son, PhD Merck Research Laboratory, Summit, NJ Presentation Outline Physics-based modeling in pharmaceutical industry Pulmonary
More informationPatricia KP Burnell Inhalation Product Development
Patricia KP Burnell Inhalation Product Development Inhaled products: types, development The critical parameters In-vitro testing Ex-vivo testing What dose? Product Development: drug medicine Safety and
More informationFormulation Considerations for Inhaled Products
Formulation Considerations for Inhaled Products Formulation Considerations of Inhaled Products Inhalation Therapy Nebulizers and Formulations Dry Powder Inhalers and Formulations Metered Dose Inhalers
More informationRDD Europe 2009 Workshop
RDD Europe 2009 Workshop 20 May 2009, Lisbon, Portugal This file is a redacted version of the presentation used during the Workshop and is suitable for electronic distribution. An Introduction to Differentiating
More informationDelivering Aerosol Medication in ICU
Delivering Aerosol Medication in ICU 18th Aug 2017 Lau Chee Lan Pharmacist HCTM PPUKM ASMIC 2017 Aerosol Therapy Part of the treatment for a variety of respiratory disease * asthma and chronic obstructive
More informationUse of Math Modelling to Understand Delivery of Biopharmaceutical Molecules to the Lung
Use of Math Modelling to Understand Delivery of Biopharmaceutical Molecules to the Lung Nia Stevens 9 th November 2016 Thanks to Richard Kaye, James Mitchell, Dave Prime at GSK Bahman Asgharian and Owen
More informationIdentification of crystalline forms suitable for inhalation in drug discovery
Identification of crystalline forms suitable for inhalation in drug discovery Valentina Diana Di Lallo Chiesi Farmaceutici - Corporate R&D Preclinical Analytics & Early Formulations Department Crystallization:
More informationNEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS
NEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS Douglas S. Gardenhire, Ed.D, RRT-NPS MODULE 1 Manipulate Small Volume Nebulizers by Order or Protocol 1 Objectives for Module 1 At the end of
More informationRespiratory. Martin Jetzer DDL27 Edinburgh December 2016
Respiratory Investigating the Effect of the Force Control Agent Magnesium Stearate in Fluticasone Propionate Dry Powder Inhaled Formulations with Single Particle Aerosol Mass Spectrometry Martin Jetzer
More informationCAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES
xxx Qualicaps CAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES There is a wide range of devices available to deliver inhalation therapies, but there is increasing
More informationCase Study 1: Pharmaceutical Development of EXUBERA
Case Study 1: Pharmaceutical Development of EXUBERA Nancy Harper, PhD Research Fellow, Parenteral Development Center of Emphasis Pfizer Global R&D IPAC-RS Conference November 2006 1 EXUBERA Insulin human
More informationDevice Design Similarity
Device Design Similarity Dave Parkins Director DPI Product Development PQRI Workshop on Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products. Bethesda March 9-10, 2009 Device Similarity
More informationAppendix M: Device Technique
Nursing Care of Dyspnea: The 6th Vital Sign in Individuals with Chronic Obstructive Pulmonary Disease (COPD) Appendix M: Device Technique Medications: Inhalation Devices Medications come in many forms.
More informationAssessing Quality of Inhaled Products And Links to Efficacy and Safety
Assessing Quality of Inhaled Products And Links to Efficacy and Safety Prasad Peri, PhD ONDQA 2011 IPAC-RS Conference Bringing Value To The Patient In A Changing World March 30, 2011 1 Outline of the Presentation
More informationOPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER
OPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER US FDA guidance for the in vitro demonstration of bioequivalence in a generic nebuliser directly references
More informationNovel drug delivery system. Nanos-in-Micros
Novel drug delivery system Nanos-in-Micros Janne Raula The annual symposium of the Finnish Society of Physical Pharmacy February 9 th, 2012 Medicinal treatment Indications -Neurosurgery -General surgery
More informationTEPZZ _7584 A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/00 ( ) A61K 31/439 (2006.
(19) TEPZZ _784 A_T (11) EP 3 17 842 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 07.06.17 Bulletin 17/23 (1) Int Cl.: A61K 9/00 (06.01) A61K 31/439 (06.01) (21) Application number: 1197874.9
More informationInhaled Therapy for TB
7 th International Workshop on Clinical Pharmacology of TB Drugs Inhaled Therapy for TB Edward A. Nardell, MD Brigham & Women s Hospital Harvard Medical School No conflicts of interest 1 1. Capreomycin
More informationFRI aerosol. deposition. A unique way to look at regional inhaled drug deposition.
FRI aerosol deposition A unique way to look at regional inhaled drug deposition www.fluidda.com EXECUTIVE SUMMARY FRI - AN UPDATE OF SCINTIGRAPHY FRI deposition technology is based on CT imaging, and uses
More informationInhalation Therapy. Inhalation Therapy
Matching Device and Patient Matching Patient to the Device Søren Pedersen University of Southern Denmark Kolding Hospital Anatomical factors (age) Training and education Delivered dose Psycomotor skills
More informationResearch Article. *Corresponding author Mahesh M.Giri
Scholars Academic Journal of Pharmacy (SAJP) ISSN 2320-4206 Sch. Acad. J. Pharm., 2013; 2(3):260-267 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationUniversity of Groningen. Adhesive mixtures for powder inhalation Dickhoff, Bastiaan Hendrikus Jozef
University of Groningen Adhesive mixtures for powder inhalation Dickhoff, Bastiaan Hendrikus Jozef IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationIPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.
IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Case Study: Pharmacokinetics and Pharmacodynamics of Tiotropium and Salmeterol Following Parallel Administration in COPD Patients Using Different
More informationAppendix E: Device Technique
Adult Asthma Care Guidelines for Nurses: Promoting Control of Asthma Appendix E: Device Technique Medications: Inhalation Devices Adapted with permission from The Lung Association: www.lung.ca/asthma/manage/devices.html
More informationIVIVC in Pediatric OIPs
IPAC-RS/UF Orlando Conference 2014 March 20, 2014 IVIVC in Pediatric OIPs Herbert Wachtel Declaration of Conflicts of Interest H. Wachtel is employee of Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.
More informationThe pulmonary route is gaining increasing
ELECTRONICALLY REPRINTED FROM FEBRUARY 2014 Pulmonary Drug Delivery Particle Engineering for Inhaled Therapeutics Moderated by Adeline Siew, PhD Industry experts discuss the various factors affecting drug
More informationDry powder inhalers for pulmonary drug delivery
Review Dry powder inhalers for pulmonary drug delivery HW Frijlink & AH De Boer Department of Pharmaceutical Technology and Biopharmacy, Groningen University Institute for Drug 1. Introduction 2. The target
More informationA multitude of devices
A multitude of devices Dr Andrew Scroop Respiratory Consultants 15 th September 2018 STEPWISE PHARMACOLOGICAL MANAGEMENT OF STABLE COPD COPD Inhalers MILD FEV 1 60 80% predicted few symptoms breathless
More informationEverything for Inhalation
Everything for Inhalation Everything for Inhalation Inhalation drug product development at Hovione has a strong focus on formulation for Dry Powder Inhalers (DPI), particularly for capsule-based and reservoir-based
More informationInhalation Product Research at FDA
Inhalation Product Research at FDA Changning Guo Ph. D., Chemist Division of Pharmaceutical Analysis FDA/CDER/OPS/OTR 2016 GPhA CMC workshop, May 17, 2016 Disclaimer: This presentation reflects the views
More informationFRI aerosol. deposition. A unique way to look at regional inhaled drug deposition.
FRI aerosol deposition A unique way to look at regional inhaled drug deposition www.fluidda.com EXECUTIVE SUMMARY Since 2005, Functional Respiratory Imaging (FRI) has been used many times to evaluate the
More informationIvax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence
Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children
More informationADDITIONAL TECHNOLOGIES FOR PRESSURIZED METERED DOSE INHALERS. Steve Newman Scientific Consultant Nottingham, UK
THE PRESS-AND-BREATHE pmdi ADDITIONAL TECHNOLOGIES FOR PRESSURIZED METERED DOSE INHALERS Steve Newman Scientific Consultant Nottingham, UK steve.newman@physics.org Compact, portable, convenient Asthma
More informationAn update on inhalation devices
OPTIMIZING INHALED DRUG DELIVERY An update on inhalation devices Contents 1. Introduction...1 2. History of spacers... 1 3. Working of a spacer... 2 4. Advantages of spacer devices... 3 5. Who should
More informationRespiratory Therapy. Medical/Scientific/General Background
Respiratory Therapy Medical/Scientific/General Background Marketing Europe Dr. Rainer Jakobs PMM Europe 1 Dr. Rainer Jakobs, PMM Europe RT Medical/Scientific/General Background 2 Dr. Rainer Jakobs, PMM
More informationHow can I benefit most from my COPD medications?
Fact Sheet: COPD Medications and Delivery Devices How can I benefit most from my COPD medications? COPD medications can improve your symptoms. By taking the right medication at the right time, you can
More information2008 IPAC-RS Conference Doing the Right Thing Science, Quality and Patient Focus
2008 IPAC-RS Conference Doing the Right Thing Science, Quality and Patient Focus Patient Perspective Alpha-1 1 Foundation John W. Walsh Patient Focus Personal perspective Challenges and lessons Importance
More informationUsing an Inhaler and Nebulizer
Using an Inhaler and Nebulizer Introduction An inhaler is a handheld device that is used to deliver medication directly to your airways. A nebulizer is an electric or battery powered machine that turns
More informationPaediatric pulmonary drug delivery: considerations in asthma treatment
Review Paediatric pulmonary drug delivery: considerations in asthma treatment 1. Introduction 2. Guideline recommendations 3. Factors affecting drug delivery to the lung 4. Nebulisers 5. Metered-dose inhalers
More informationGo With the Flow REGULATORY LANDSCAPE. Mark Copley at Copley Scientific
Go With the Flow Image: Guzel Studio shutterstock.com Increasing global requirements for efficacious, inexpensive products to treat respiratory illnesses are driving the development of inhaled generics.
More informationI. Subject: Medication Delivery by Metered Dose Inhaler (MDI)
I. Subject: Medication Delivery by Metered Dose Inhaler (MDI) II. Policy: Aerosol medication administration by metered dose inhaler will be performed upon a physician's order by Respiratory Therapy personnel.
More informationInteractions, structure and process: relevant aspects of the development of lactose-based formulations and devices for dry powder inhalation
1 ORIGINAL TITLE Interactions, structure and process: relevant aspects of the development of lactose-based formulations and devices for dry powder inhalation PROPOSED TITLES Aspects of the development
More informationInnovation in formulations to improve aerosol delivery
Innovation in formulations to improve aerosol delivery Peter York Chief Scientist, CrystecPharma DDL Conference Edinburgh, 7-9 th December 2016 Triumvirate in design of inhalation medicines Nebulisers,
More informationSELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS
SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS Poonam Sheth, PharmD, PhD, Research Scientist, Inhalation Matthew T. Marmura, Research Scientist, Inhalation Recipharm is frequently asked to help
More informationUnderstanding cascade impaction and its importance for inhaler testing
Understanding cascade impaction and its importance for inhaler testing Mark Copley, Technical Sales Manager Inhalation product development is an important area of activity for the pharmaceutical sector.
More informationDry powder inhalation de Boer, Anne; Hagedoorn, Paul; Hoppentocht, Marcel; Buttini, F; Grasmeijer, F.; Frijlink, H.W.
University of Groningen Dry powder inhalation de Boer, Anne; Hagedoorn, Paul; Hoppentocht, Marcel; Buttini, F; Grasmeijer, F.; Frijlink, H.W. Published in: Expert Opinion on Drug Delivery DOI: 10.1080/17425247.2016.1224846
More informationImproved Aerosol Deposition Profiles from Dry Powder Inhalers
1 University of Hertfordhire Improved Aerosol Deposition Profiles from Dry Powder Inhalers Submitted to the University of Hertfordshire in partial fulfilment of the requirements of the degree of Doctor
More informationINHALATION DRUG DELIVERY DEVICES: BRONCHODILATORS NATTAWAT NATPHOBSUK, MD
INHALATION DRUG DELIVERY DEVICES: BRONCHODILATORS NATTAWAT NATPHOBSUK, MD BACKGROUND SHORT-ACTING 2 -AGONISTS SHORT-ACTING 2 -AGONISTS (SABAS) USED EXTENSIVELY IN THE MANAGEMENT OF PULMONARY DISEASES SINCE
More informationNovolizer Technical Aspects
Novolizer Technical Aspects Dr José Mª Negro Alvarez H.U. Virgen de la Arrixaca.. Murcia (España) a) Profesor Asociado de Alergología. Universidad de Murcia (España) a) Contents Design and function of
More informationChallenges in Nonclinical Development of Inhalation Drug Products
Challenges in Nonclinical Development of Inhalation Drug Products Luqi Pei, Ph.D. Senior Pharmacologist DPARP, CDER August 6, 2015 Rockville, MD Disclaimer This speech reflects the views of the speaker
More informationSELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS. Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical
SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical www.cirruspharm.com February 2014 INTRODUCTION Cirrus, a Kemwell company, is frequently
More informationInhaled Drug Delivery Systems
Inhaled Drug Delivery Systems eve r y b r e a t h f o r yo u Millions of people suffer every day from chronic respiratory diseases and these constitute a large part of a physician s practice. According
More informationGMMMG Asthma Formulary Inhaler Options August 2017
Regular Preventer Beclometasone Beclometasone Beclometasone Brand name Qvar Easi-Breathe Clenil Modulite Easyhaler Device MDI MDI DPI Strengths 50 microgram 100 microgram 200 microgram Adult asthma 2 inhalations
More informationThe Novolizer s : overcoming inherent problems of dry powder inhalers
Respiratory Medicine (2004) Supplement A, S17 S21 ARTICLE IN PRESS The Novolizer s : overcoming inherent problems of dry powder inhalers Dieter Kohler* Chefarzt Innere Medizin und Pneumologie, Fachkrankenhaus
More information"GUARDING AGAINST TUBERCULOSIS AS A FIRST RESPONDER"
MAJOR PROGRAM POINTS "GUARDING AGAINST TUBERCULOSIS AS A FIRST RESPONDER" Training For THE CDC "TUBERCULOSIS PREVENTION GUIDELINES" "Quality Safety and Health Products, for Today...and Tomorrow" Outline
More informationPARTICLE-PARTICLE INTERACTIONS BETWEEN TAILORED MANNITOL CARRIER PARTICLES AND DRUG PARTICLES FOR INHALATION
PARTICLE-PARTICLE INTERACTIONS BETWEEN TAILORED MANNITOL CARRIER PARTICLES AND DRUG PARTICLES FOR INHALATION DOCTORAL THESIS SUBMITTED IN THE FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR IN
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationWhat You Need to Know about Metered-Dose Inhalers and the HFA Propellant
What You Need to Know about Metered- Inhalers and the HFA Propellant There are a number ways to deliver inhaled medication. They include: Metered-dose inhaler () Metered-dose inhaler with spacer/holding
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationINHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop
INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers
More informationCaption: The equipment required for testing Fluticasone Propionate (FP) Inhalation Powder in line with a new product-specific monograph (USP36-NF31).
Product-specific FDA guidance, and product-specific pharmacopeial monographs, point to the use of test equipment, some of which isn t included in the general USP/Ph. Eur. chapters for orally inhaled products
More informationAsthma in Day to Day Practice
Asthma in Day to Day Practice VIJAY.K.VANAM Financial relationships: Disclosures Employed at Mercy Medical Center, Mason City. Nonfinancial relationships: I receive no financial gain from any pharmaceutical
More informationEffects of viscosity, pump mechanism and nozzle geometry on nasal spray droplet size
ILASS Europe 21, 23rd Annual Conference on Liquid Atomization and Spray Systems, Brno, Czech Republic, September 21 P. Kippax 1, J. Suman 2, A. Virden 1* and G. Williams 3 1 Malvern Instruments, Grovewood
More informationScintigraphic comparison of budesonide deposition from two dry powder inhalers
Eur Respir J 2000; 16: 178±183 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2000 European Respiratory Journal ISSN 0903-1936 Scintigraphic comparison of budesonide deposition from two
More informationWhat you need to know about inhalers and how to use them Henry Chrystyn PhD, FRPharmS and David Price MA, MRCGP, DRCOG
What you need to know about inhalers and how to use them Henry Chrystyn PhD, FRPharmS and David Price MA, MRCGP, DRCOG VM The authors describe the problems that arise with metered-dose and dry-powder inhalers,
More informationEquivalence Evaluation of Valved Holding Chambers (VHCs) with Albuterol Pressurized Metered Dose Inhaler (pmdi)
Respiratory Drug Delivery Europe 2017 Nagel and Suggett Equivalence Evaluation of Valved Holding Chambers (VHCs) with Albuterol Pressurized Metered Dose Inhaler (pmdi) Mark W. Nagel and Jason A. Suggett
More informationYear in review. Vit Perlik Director of Regulatory Science and Clinical Development
Year in review Vit Perlik Director of Regulatory Science and Clinical Development Content Year in review Covering September 2013 to September 2014 Where the regulation goes selection of events for illustration
More informationEffect of Rise in Simulated Inspiratory Flow Rate and Carrier Particle Size on Powder Emptying From Dry Powder Inhalers
Effect of Rise in Simulated Inspiratory Flow Rate and Carrier Particle Size on Powder Emptying From Dry Powder Inhalers Received March 3, 2000; Accepted April 5, 2000, Published April 20, 2000 Varsha Chavan
More informationNovel Application of an Old Excipient L-Leucine- Improving Physical and. Aerosolization Stability of Spray Dried Amorphous DPI Formulations.
1 Novel Application of an Old Excipient L-Leucine- Improving Physical and Aerosolization Stability of Spray Dried Amorphous DPI Formulations. Nivedita Shetty 1, Dmitry Zemlyanov 2, Qi (Tony) Zhou 1 1 Department
More informationCharacterizing the Performance of Metered Dose Inhalers with Add-On Devices: New Methods For Clinically Relevant Testing
INSTRUMENTATION» Characterizing the Performance of Metered Dose Inhalers with Add-On Devices: New Methods For Clinically Relevant Testing Mark Copley Director Copley Scientific The recent introduction
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS
European Medicines Agency Inspections London, 16 February 2005 Doc Ref.: EMEA/CHMP/QWP/49313/2005 corr. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF
More informationInhalers and nebulizers: basic principles and preliminary measurements
Inhalers and nebulizers: basic principles and preliminary measurements Ondrej Misik 1*, Frantisek Lizal 1, Vahid Farhikhteh Asl 2, Miloslav Belka 1, Jan Jedelsky 1, Jakub Elcner 1 and Miroslav Jicha 1
More informationEXPERT OPINION: REVIEWING CURRENT THINKING ON THE IN VIVO BEHAVIOUR OF PARTICLES IN THE EXTRA-FINE REGION
EXPERT OPINION: REVIEWING CURRENT THINKING ON THE IN VIVO BEHAVIOUR OF PARTICLES IN THE EXTRA-FINE REGION The inhalation route is a fast and effective way of delivering medication, both locally to the
More informationGeneric Inhaled Medications
Generic Inhaled Medications Financial Interest Disclosure (over the past 24 months) Irvin Mayers Company Speaker Advisory Research Medimmune Novartis GSK Boehringer Ingelheim CADTH Health Canada Financial
More informationIssues in TB Infection Control. Stopping transmission of TB. The Issue: Transmission of TB. TB Infection Control
Curry International TB Center Issues in TB Infection Control Lisa Chen, MD CITC TB Intensive, Oct. 2017 Stopping transmission of TB TB Infection Control A combination of measures aimed at minimizing the
More informationInh l a t a i tional D i ev ces for the Ou O t u pat p ie i nts Dr Sunil Sharma Senior Resident
Inhalational ldevices for the Outpatients Dr Sunil Sharma Senior Resident Introduction Inhalational ltherapy allows selective treatment t tof lungs achieving high concentrations in airway minimizing systemic
More informationProcess Drift and it s Resolution in the Manufacture of Drug Products. MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations
Process Drift and it s Resolution in the Manufacture of Drug Products MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations Ed Warner, Merck MMD December 2, 2010 PQRI-FDA Workshop on Process
More informationImportant Principles of Aerosol Therapy for Your Patients
Important Principles of Aerosol Therapy for Your Patients Disclaimer Appendix 3 Declaration of Vested Interest Form Name of presenter: David Henry RRT Name of employer: DeVilbiss Healthcare Inc. Definition:
More informationDevelopment of a Dry Powder Multi-dose Inhaler using Computational Modeling
ENGINEER - Vol. XXXXII, No. 03, pp. [57-65], 2009 The Institution of Engineers, Sri Lanka Development of a Dry Powder Multi-dose Inhaler using Computational Modeling M.A.D.A.Sudeera, V.P.C.Dassanayake,
More informationHigher lung deposition with Respimat Soft Mist Inhaler than HFA-MDI in COPD patients with poor technique
ORIGINAL RESEARCH Higher lung deposition with Respimat Soft Mist Inhaler than in COPD patients with poor technique Peter Brand 1 Bettina Hederer 2 George Austen 3 Helen Dewberry 3 Thomas Meyer 4 1 RWTH,
More informationAssessing the role of breathing simulators in OIP testing
As first AppeAred in Inhalation April 2014 www.inhalationmag.com Assessing the role of breathing simulators in OIP testing Exploring how the application of patient-representative inhalation profiles can
More informationCAPSULES Films & Foils MACHINES INSPECTION SYSTEMS. Partnering in Excellence
CAPSULES Films & Foils MACHINES INSPECTION SYSTEMS Partnering in Excellence Our Vision, Mission and Values 2 Comprehensive Solution for cdpi: Opportunities, Trends & Possibilities Webinar 9 th November
More informationGuidance for Industry
Guidance for Industry Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products Chemistry, Manufacturing, and Controls Documentation DRAFT GUIDANCE This document is being distributed for comment
More information8/13/11. RSPT 1410 Humidity & Aerosol Therapy Part 3. Humidification Equipment. Aerosol Therapy
1 RSPT 1410 Humidity & Aerosol Therapy Part 3 Wilkins: Chapter 35, p. 775-799 Cairo: Chapter 4, p. 88-143 2 Humidification Equipment A humidifier is a device that adds molecular liquid (e.g. water vapor)
More informationUniversity of Groningen. Dry powder inhalation of antibiotics Hoppentocht, Marcel
University of Groningen Dry powder inhalation of antibiotics Hoppentocht, Marcel IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More information